Oura has made its IPO filing public, giving a detailed look at the smart ring’s business and the growing scope of its women’s health strategy.
Women make up 72% of Oura’s 5 million paid members, giving the company a large built-in audience as it expands from sleep and cycle tracking into fertility, pregnancy, postpartum, perimenopause, menopause, and healthy aging.
Oura combines biometric data with bloodwork, glucose data, health records, and other inputs to build what it describes as a “personal health system of record.” To interpret biometric signals and longitudinal trends, Oura has developed a proprietary, AI-powered women’s health coach, with plans to develop additional domain-specific models.
Pushing deeper into clinical care, its menopause symptom tracker is being integrated by healthcare and virtual care partners like Alloy and Maven, while the company is also seeking a patent for a pregnancy complication detection tool.
Powered by scale, Oura members have generated more than 42 billion hours of longitudinal biometric data, and the audience is still expanding — 33% of new members are first-time wearable buyers.
Oura is going public with women’s health embedded across its user base, product roadmap, data strategy, and healthcare ambitions. Now, it has the opportunity to turn that foundation into a leading women’s health platform.
